CClinicalTrials.gg
Sign In
Status unknownNCT04921098Updated Jan 11, 2022

CPC in Adult Refractory Glaucoma

An interventional study of Diode Laser Cyclophotocoagulation in Refractory Glaucoma, sponsored by Sohag University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the relative effectiveness and safety of diode laser cyclophotocoagulation procedure to reduce IOP and relieve pain in adult patients with refractory glaucoma.

Read the detailed description

A hospital -based, prospective interventional non comparative case series study.This study will be conducted on patients with refractory glaucoma whose ages are 18 years and older.They will be subjected to Transscleral Diode Laser Cyclophotocoagulation.

Postoperative evaluation will be scheduled for the first day postoperative, then 1 week later and then at 1st, 3rd, month postoperative.

02

Conditions studied

  • Refractory Glaucoma

Browse trials for

03

In context

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's planned enrollment of 25 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:

    1. Patients with refractory glaucoma aging 18 years and older.
    2. Both sexes are included.
    3. Patients Capable of giving informed consent.
    4. Pseudophkic glaucoma.
    5. Aphakic glaucoma.
    6. Silicon oil induced glaucoma.
    7. Neovascular glaucoma.
    8. Inflammatory glaucoma.

Exclusion Criteria:

  1. Patients \<18 years of age.
  2. Patients controlled on regular antiglaucomatous therapy.
  3. Patients who cannot do regular follow up visits.
  4. Diffuse scleral staphyloma at the site of CPC.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Refractory glaucoma

    Procedure: Diode Laser Cyclophotocoagulation

Interventions

  • ProcedureDiode Laser Cyclophotocoagulation

    A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.

06

What researchers measure

Primary outcomes

  1. change in intraocular pressure

    IOP measuring using Goldmann applanation tonometer.

    Time frame: First day postoperative and 1 week

07

Study locations

1 of 1 sites recruiting
  • Sohag University
    Sohag, Egypt
    • Osama R Elsherif, Professor · Contact
    Recruiting
08

References and documents

Publications

  • Ansari E, Gandhewar J. Long-term efficacy and visual acuity following transscleral diode laser photocoagulation in cases of refractory and non-refractory glaucoma. Eye (Lond). 2007 Jul;21(7):936-40. doi: 10.1038/sj.eye.6702345. Epub 2006 Apr 21. PubMed 16628239 ↗
  • Lai JS, Tham CC, Chan JC, Lam DS. Diode laser transscleral cyclophotocoagulation in the treatment of chronic angle-closure glaucoma: a preliminary study. J Glaucoma. 2003 Aug;12(4):360-4. doi: 10.1097/00061198-200308000-00011. PubMed 12897582 ↗
  • Nassiri N, Kamali G, Rahnavardi M, Mohammadi B, Nassiri S, Rahmani L, Nassiri N. Ahmed glaucoma valve and single-plate Molteno implants in treatment of refractory glaucoma: a comparative study. Am J Ophthalmol. 2010 Jun;149(6):893-902. doi: 10.1016/j.ajo.2010.01.025. Epub 2010 May 8. PubMed 20451896 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04921098
Lead sponsor
Sohag University
Responsible party
Mina Abdelmalek Besada (Principal Investigator, Sohag University) — Principal investigator
First posted
Jun 10, 2021
Start date
Jul 1, 2021
Primary completion
Apr 2022 (estimated)
Completion
Apr 2022 (estimated)
Last update
Jan 11, 2022

Study contacts

Mina A Besada, Resident
Contact
mena011205@med.sohag.edu.eg
01280899267
Ismail M Abdellatif, Professor
Contact
01223629352

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glaucoma→

Other studies from this sponsor

Sohag University

Start the discussion